INAB IN8bio Inc
1,208
$0.994
$0.006
(0.60%)
| Watchers | 1,208 |
| 52-Wk Low | $0.65 |
| 52-Wk High | $3.48 |
| Market Cap | $43.29M |
| Volume | 44,440.00 |
| 52-Wk High | $3.48 |
| 52-Wk Low | $0.65 |
12 titres de soins de sant en mouvement lors de la session apr s-cl ture le 09/04/2024Benzinga • 27 days ago
Gagnants
Le titre IN8bio (NASDAQ:INAB) a augment mardi de 31,19% 1,43 dollars lors de la session after-market.
L'action ImmuCell (NASDAQ:ICCC) a grimp de 11,11% 5,80 dollars.
L'action aTyr...
Share to Feed
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Laidlaw initiated coverage on shares of IN8bio (NASDAQ:INAB Free Report) in a report published on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $7.50 price...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated Remained in Remission...
Compugen (NASDAQ:CGEN Get Free Report) and IN8bio (NASDAQ:INAB Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two...
New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented.The platform has demonstrated...
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present...
Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapyNEW YORK, Feb. 14, 2024...
Shares of IN8bio, Inc. (NASDAQ:INAB Get Free Report) fell 7.7% during trading on Thursday . The company traded as low as $1.19 and last traded at $1.20. 618,406 shares changed hands during...